Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 01:55:50 2024-06-17 pm EDT 5-day change 1st Jan Change
0.13 CAD 0.00% Intraday chart for Algernon Pharmaceuticals Inc. -16.13% +100.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset CI
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company MT
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc. CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Algernon Pharmaceuticals Increased Private Placement MT
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast MT
Algernon Pharmaceuticals Brief: Says Received Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD CI
Algernon Pharma in LOI For Acquisition of its Chronic Cough Research Program For US$2 Million and 20% Equity Stake MT
Algernon Pharmaceuticals Brief: Announcing LOI for Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for US$2 Million and a 20% Equity Position MT
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023 CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding CI
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities CI
Algernon Pharmaceuticals Engage Maxim Group to Explore Spin-Off of Ifenprodil Phase 2 Chronic Cough Drug Development Program MT
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference MT
Chart Algernon Pharmaceuticals Inc.
More charts
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
Calendar
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. AGN Stock
  4. News Algernon Pharmaceuticals Inc.
  5. Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company